Clinical Trial Update: Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) [Phase 2]

View source ↗

Summary

Phase 2 study of semaglutide for non-alcoholic fatty liver disease in HIV infection completed, with results posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-05-17